Screener
Theravance Biopharma TBPH Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from option exercises | 241 | — |
| Repurchase of shares to satisfy tax withholding | (5,818) | (874) |
| Net cash used in financing activities | (5,577) | (854) |
| Net increase in cash, cash equivalents, and restricted cash | 120,295 | 72,817 |
| Cash, cash equivalents, and restricted cash at beginning of period | 168,642 | 38,633 |
| Cash, cash equivalents, and restricted cash at end of period | $288,937 | $111,450 |
| Supplemental disclosure of cash flow information | ||
| Cash (received) paid for income taxes, net | $(351) | $4 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's net change in cash?
- Theravance Biopharma (TBPH) reported net change in cash of $120.3M in Q1 2026.
- How has Theravance Biopharma's net change in cash changed year-over-year?
- Theravance Biopharma's net change in cash increased by 65.2% year-over-year, from $72.82M to $120.3M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Theravance Biopharma's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude